Aliso Viejo, California - March 1, 2020. Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth. They have outgrown their five story, 207,000 square foot building in Southern California amid their growing presence in the neurovascular industry.

“With the backing of Terumo, MicroVention has undergone a remarkable evolution in the past several years as we continue to strive toward our vision of becoming the global leader in the industry. The blend of MicroVention’s robust pipeline combined with best-in-class products, has allowed us to grow at a phenomenal rate. With 3 recent FDA PreMarket Approvals (PMAs) added to our aneurysm portfolio, which include the LVIS™ stent, FRED™ flow diversion device, and WEB™ intrasaccular device, our reach in the global neuroendovascular marketplace continues to solidify,” said Matt Fitz, Chief Strategy and Innovation Officer.

MicroVention’s expansion includes an additional 30,700 square feet to accommodate approximately 175 Associates that are needed to support the design and manufacturing of medical devices for the treatment of cerebrovascular diseases that include brain aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. The company is comprised of approximately < 3,000 dedicated Associates and distributors worldwide with a reach of over 75 countries. In addition, they have offices in Europe, China, and Costa Rica.

“As we continue to expand year-over-year, it is an exciting time to be a part of MicroVention. Our corporate culture, vision, mission, and core values unite our diverse workplace as we strive to be the very best at what we do,” said Cherie Henket, J.D., Senior Vice President, Global Human Resources, “All of us here are passionate about making a difference and enabling the advancement of the industry and patient care.”

 

About MicroVention, Inc.

Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases.

Headquartered in California, MicroVention products are sold in more than 75 nations through a direct sales organization alongside strategic distribution partnerships.

 

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries. The company's extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo pursues quality in all we do – from product excellence to customer care – in order to give patients a better tomorrow.

www.terumo.com

 

Media Contact:
Cathy Demyanovich
Sr. Director, Corporate Communications
MicroVention. Inc.
+1-714-247-8000